{"id":48437,"date":"2025-06-12T06:38:03","date_gmt":"2025-06-12T04:38:03","guid":{"rendered":"https:\/\/theark.ch\/news\/un-test-rapide-contre-les-bacteries-resistantes-aux-antibiotiques-developpe-par-la-start-up-valaisanne-gadia\/"},"modified":"2025-06-12T10:21:10","modified_gmt":"2025-06-12T08:21:10","slug":"un-test-rapide-contre-les-bacteries-resistantes-aux-antibiotiques-developpe-par-la-start-up-valaisanne-gadia","status":"publish","type":"post","link":"https:\/\/theark.ch\/en\/news\/un-test-rapide-contre-les-bacteries-resistantes-aux-antibiotiques-developpe-par-la-start-up-valaisanne-gadia\/","title":{"rendered":"a rapid test for antibiotic-resistant bacteria developed by valais start-up gadia"},"content":{"rendered":"\n<h5 class=\"wp-block-heading\"><strong><strong>valais start-up\u00a0gadia\u00a0is launching an innovative test that can detect carbapenem-resistant bacteria in just 15 minutes. this fast and accurate solution could be a game-changer for hospital and private laboratories.<\/strong><\/strong><\/h5>\n\n\n\n<p><a href=\"https:\/\/gadia.ch\/\" target=\"_blank\" rel=\"noopener\">gadia<\/a>, based at the <a href=\"https:\/\/bioark.ch\/\" target=\"_blank\" rel=\"noopener\">bioark<\/a> technological site in monthey, continues to innovate in the field of rapid diagnostic testing. its new product can identify five types of carbapenemases, enzymes produced by antibiotic-resistant bacteria. these are classified as an urgent threat by global health authorities.<\/p>\n\n\n\n<p>with the rise of resistant bacteria, traditional diagnostic methods, which are lengthy and costly, are showing their limitations. \u2018<em>our test reduces the analysis time to 15 minutes, compared to several hours or even days with conventional techniques,<\/em>\u2019 explains\u00a0percevent ducrest,\u00a0founder of gadia. based on lateral flow assay technology (similar to covid tests), it offers 94-100% accuracy.<\/p>\n\n\n\n<p>designed for hospital and private laboratories, this test meets a growing need. \u2018<em>tenders are multiplying in europe as hospitals seek reliable and cost-effective solutions<\/em>,\u2019 he adds.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><strong>a niche strategy<\/strong><\/h5>\n\n\n\n<p>gadia stands out by positioning itself in specific markets, far from massive competition. \u2018<em>we don\u2019t do consumer testing, but we target segments where expertise is key,<\/em>\u2019 emphasises percevent ducrest.<\/p>\n\n\n\n<p>manufactured entirely in valais, these tests are competitively priced despite their high quality. \u2018<em>our entire value chain is controlled locally. we even work with students and retirees to strengthen our team<\/em>,\u2019 he explains.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><strong>outlook and recognition<\/strong><\/h5>\n\n\n\n<p>several successful tenders in europe confirm the test\u2019s potential. \u2018<em>we have contracts ranging from 100 tests to 100,000 over six years<\/em>,\u2019 reveals the founder. these successes are enabling gadia to consider new recruitment and investments, particularly in european ivdr certification.<\/p>\n\n\n\n<p>this project also illustrates the start-up\u2019s resilience. \u2018<em>it hasn\u2019t been easy every day, but today we are proving that hard work pays off,<\/em>\u2019 concludes percevent ducrest, grateful to partners such as&nbsp;<a href=\"http:\/\/www.theark.ch\/\">the ark<\/a>&nbsp;and&nbsp;<a href=\"https:\/\/www.cimark.ch\/\" target=\"_blank\" rel=\"noopener\">cimark<\/a>.<\/p>\n\n\n\n<p>with this new test, gadia confirms its place among the innovative players in healthcare in valais\u2026 and far beyond.<\/p>\n\n\n\n<p><strong>more info:&nbsp;<a href=\"https:\/\/gadia.ch\/\" target=\"_blank\" rel=\"noopener\">www.gadia.ch<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>valais start-up\u00a0gadia\u00a0is launching an innovative test that can detect carbapenem-resistant bacteria in just 15 minutes. this fast and accurate solution could be a game-changer for hospital and private laboratories.<\/p>\n","protected":false},"author":3,"featured_media":48400,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[210],"tags":[],"class_list":["post-48437","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-sciences-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/posts\/48437","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/comments?post=48437"}],"version-history":[{"count":2,"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/posts\/48437\/revisions"}],"predecessor-version":[{"id":48440,"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/posts\/48437\/revisions\/48440"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/media\/48400"}],"wp:attachment":[{"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/media?parent=48437"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/categories?post=48437"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/theark.ch\/en\/wp-json\/wp\/v2\/tags?post=48437"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}